Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience-Reference-Cited by-同舟云学术

Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience

Published:2016-09 Issue: Volume:99 Page:111-116
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Bluthgen M.V.,Boutros C.,Fayard F.,Remon J.,Planchard D.,Besse B.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Malignant thymoma: current status of classification and multimodality treatment;Schmidt-Wolf;Ann. Hematol.,2003

2. The 2015 world health organization classification of tumors of the thymus: continuity and changes;Marx;J. Thorac. Oncol.,2015

3. Thymic carcinoma: state of the art review;Eng;Int. J. Radiat. Oncol.,2004

4. KIT(CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas;Pan;J. Pathol.,2004

5. A review of prognostic factors in thymic malignancies;Detterbeck;J. Thorac. Oncol.,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study;Thoracic Cancer;2023-11-27

2. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis;Recent Patents on Anti-Cancer Drug Discovery;2023-11

3. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis;Cancer Medicine;2023-06-23

4. Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma;Thoracic Cancer;2023-04-10

5. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases;Anti-Cancer Drugs;2022-12-05